Buy Ziprasidone (Geodon) online

Buy Geodon (Ziprasidone Hydrochloride) atypical antipsychotic
Cheap qualitative Ziprasidone 20 mg, 40 mg, 80 mg capsules online



HOW AND WHERE TO BUY ZIPRASIDONE (GEODON) 20 MG, 40 MG, 80 MG CAPSULES OR TABLETS ONLINE:

GEODON: USE IN SPECIFIC POPULATIONS

Pregnancy

Pregnancy Category C

In animal studies ziprasidone demonstrated developmental toxicity, including possible teratogenic effects at doses similar to human therapeutic doses. When ziprasidone was administered to pregnant rabbits during the period of organogenesis, an increased incidence of fetal structural abnormalities (ventricular septal defects and other cardiovascular malformations and kidney alterations) was observed at a dose of 30 mg / kg per day (3 times the MRHD of 200 mg/day on a mg / m2 basis). There was no evidence to suggest that these developmental effects were secondary to maternal toxicity. The developmental no-effect dose was 10 mg / kg per day (equivalent to the MRHD on a mg / m2 basis). In rats, embryofetal toxicity (decreased fetal weights, delayed skeletal ossification) was observed following administration of 10 to 160 mg / kg per day (0.5 to 8 times the MRHD on a mg / m2 basis) during organogenesis or throughout gestation, but there was no evidence of teratogenicity. Doses of 40 and 160 mg / kg per day (2 and 8 times the MRHD on a mg / m2 basis) were associated with maternal toxicity. The developmental no-effect dose was 5 mg / kg per day (0.2 times the MRHD on a mg / m2 basis).

There was an increase in the number of pups born dead and a decrease in postnatal survival through the first 4 days of lactation among the offspring of female rats treated during gestation and lactation with doses of 10 mg / kg per day (0.5 times the MRHD on a mg / m2 basis) or greater. Offspring developmental delays and neurobehavioral functional impairment were observed at doses of 5 mg / kg per day (0.2 times the MRHD on a mg / m2 basis) or greater. A no-effect level was not established for these effects.

There are no adequate and well-controlled studies in pregnant women. Geodon (Ziprasidone) should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Non-teratogenic effects

Neonates exposed to antipsychotic drugs, during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery. There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress and feeding disorder in these neonates. These complications have varied in severity; while in some cases symptoms have been self-limited, in other cases neonates have required intensive care unit support and prolonged hospitalization.

Geodon (Ziprasidone) should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Labor and Delivery

The effect of Ziprasidone (Geodon) on labor and delivery in humans is unknown.

Nursing Mothers

It is not known whether ziprasidone or its metabolites are excreted in human milk. It is recommended that women receiving ziprasidone should not breastfeed.

Pediatric Use

The safety and effectiveness of Ziprasidone (Geodon) in pediatric patients have not been established.

Geriatric Use

Of the total number of subjects in clinical studies of ziprasidone, 2.4 percent were 65 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. Nevertheless, the presence of multiple factors that might increase the pharmacodynamic response to ziprasidone, or cause poorer tolerance or orthostasis, should lead to consideration of a lower starting dose, slower titration, and careful monitoring during the initial dosing period for some elderly patients. Ziprasidone intramuscular has not been systematically evaluated in elderly patients (65 years and over).

Renal Impairment

Because Ziprasidone (Geodon) is highly metabolized, with less than 1% of the drug excreted unchanged, renal impairment alone is unlikely to have a major impact on the pharmacokinetics of ziprasidone. The pharmacokinetics of ziprasidone following 8 days of 20 mg twice daily dosing were similar among subjects with varying degrees of renal impairment (n=27), and subjects with normal renal function, indicating that dosage adjustment based upon the degree of renal impairment is not required. Ziprasidone is not removed by hemodialysis.

Intramuscular Ziprasidone Mesylate (Geodon) has not been systematically evaluated in elderly patients or in patients with hepatic or renal impairment. As the cyclodextrin excipient is cleared by renal filtration, ziprasidone intramuscular should be administered with caution to patients with impaired renal function.

Hepatic Impairment

As ziprasidone is cleared substantially by the liver, the presence of hepatic impairment would be expected to increase the AUC of ziprasidone; a multiple-dose study at 20 mg twice daily for 5 days in subjects (n=13) with clinically significant (Childs-Pugh Class A and B) cirrhosis revealed an increase in AUC 0-12 of 13% and 34% in Childs-Pugh Class A and B, respectively, compared to a matched control group (n=14). A half-life of 7.1 hours was observed in subjects with cirrhosis compared to 4.8 hours in the control group.

Age and Gender Effects

In a multiple-dose (8 days of treatment) study involving 32 subjects, there was no difference in the pharmacokinetics of ziprasidone between men and women or between elderly ( > 65 years) and young (18 to 45 years) subjects. Additionally, population pharmacokinetic evaluation of patients in controlled trials has revealed no evidence of clinically significant age or gender-related differences in the pharmacokinetics of Ziprasidone (Geodon). Dosage modifications for age or gender are, therefore, not recommended.

Smoking

Based on in vitro studies utilizing human liver enzymes, ziprasidone is not a substrate for CYP1A2; smoking should therefore not have an effect on the pharmacokinetics of Geodon (Ziprasidone). Consistent with these in vitro results, population pharmacokinetic evaluation has not revealed any significant pharmacokinetic differences between smokers and nonsmokers.

Recent posts:

  • Buy Geodon (Ziprasidone) Online
  • Geodon prescribing information

    Copyright © Buy Ziprasidone Online